Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution-Reference-Cited by-同舟云学术

Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution

Published:2024-06-01 Issue:2 Volume:5 Page:83-92
ISSN:2719-4523
Container-title:Rheumatology and Immunology Research
language:en
Short-container-title:

Author:

Fairley Jessica L¹²,O’Rourke Rachael³⁴,Puranik Rajesh⁵⁶,Nikpour Mandana¹²⁵⁶

Affiliation:

1. The University of Melbourne , Melbourne , Victoria , Australia

2. St. Vincent’s Hospital Melbourne , Melbourne , Victoria , Australia

3. The Prince Charles Hospital , Brisbane , Queensland , Australia

4. The University of Queensland , Brisbane , Queensland , Australia

5. The University of Sydney , Sydney , New South Wales , Australia

6. Royal Prince Alfred Hospital Sydney , New South Wales , Australia

Abstract

Abstract Cardiac magnetic resonance imaging (CMR) is the gold-standard non-invasive method of assessing cardiac structure and function, including tissue characterisation. In systemic sclerosis (SSc), heart involvement (SHI) is a leading cause of mortality yet remains poorly understood. SHI is underestimated by conventional echocardiography, and CMR provides an important opportunity to better identify and quantify subtle myocardial changes including oedema and fibrosis. This review summarises current CMR techniques, the role of CMR in SSc and SHI, and the opportunities to further our understanding of its pathogenesis and management.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/rir-2024-0011/pdf

Reference53 articles.

1. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2011;8:42–54.

2. Hao Y, Hudson M, Baron M, et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis Rheumatol. 2017;69:1067–1077.

3. Fairley JL, Hansen D, Proudman S, et al. Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis. Semin Arthritis Rheum. 2024;66:152443.

4. Fairley JL, Hansen D, Burns A, et al. Contribution of Left Ventricular Diastolic Dysfunction to Survival and Breathlessness in Systemic Sclerosis-Associated Interstitial Lung Disease. J Rheumatol. 2024;51:495–504.

5. D’Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428–440.